1-
Miller E,
Vurdien JE,
White JM. The epidemiology of pertussis in England and Wales
. Communicable Disease Report Review. 1992; 2(13).
2-Heikkinen E, Xing K, Ölander R, Hytönen J, Viljanen M, Mertsola J, Hecorresponding Q. Bordetella pertussis isolates in Finland: Serotype and fimbrial expression. BMC Microbiol. 2008; 8(162).
3-Cherry J, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998; 16(20) 1901-6.
4-Ashworth L, et al. Agglutinogens and fimbriae of Bordetella pertussis. Tokai J Exp Clin Med. 1988; 13.
5-Robinson A, Irons L, Ashworth L. Pertussis vaccine: present status and future prospects. Vaccine 1985;3(1) 11-22.
6-Geuijen CA, et al. Identification and Characterization of Heparin Binding Regions of the Fim2 Subunit of Bordetella pertussis. Infect Immun. 1998; 66(5) 2256–2263.
7-Gorringe AR, Vaughan TE, Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert Rev Vaccines. 2014; 13(10) 1205–1214.
8-Alexander F, Matheson M, Fry N, Labram B, Gorring A. Antibody Response to Individual Bordetella pertussis Fimbrial Antigen Fim2 or Fim3 following Immunization with the Five- Component Acellular Pertussis Vaccine or to Pertussis Disease. Clin Vaccine Immunol. 2012; 19(11) 1776–1783.
9-Xu Y, Wang Y, Tan Y, Zhang H, Wu L, Wang L, Zhang S. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis. BMC Microbiology, 2009 9(274).
10-Chen Q, et al , Novel architectural features of Bordetella pertussis fimbrial subunit promoters and their activation by the global virulence regulator BvgA. Mol Microbiol. 2010; 77(5) 1326-40.
11-Fazekas A, Steeves R, Newmaster S. Improving sequencing quality from PCR products containing long mononucleotide repeats. Biotechniques. 2010; 48(4) 277-85.